SINOPHARM GRP CO. H YC 1 financial statements, including revenue, expenses, profit, and loss

The total revenue of X2S for the last semiannual is 38.17 B EUR, and it's 3.05% higher compared to the previous semiannual. The net income of H1 24 is 479.74 M EUR.